Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 10.10
Change Today 0.00 / 0.00%
Volume 0.0
As of 10:24 AM 04/21/15 All times are local (Market data is delayed by at least 15 minutes).

d-pharm ltd (DPRM) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/2/14 - $18.92
52 Week Low
02/5/15 - $9.70
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for D-PHARM LTD (DPRM)

Related News

No related news articles were found.

d-pharm ltd (DPRM) Related Businessweek News

No Related Businessweek News Found

d-pharm ltd (DPRM) Details

D-Pharm LTD., a drug-development company, focuses on the development of drugs for the treatment of central nervous system conditions. Its products pipeline includes DP-VPA, a generic anti-epileptic drug, which has completed the phase II clinical-stage trial for the treatment of various seizures, as well as for the treatment of manic depression and prophylaxis of migraine; and THR-18, a thrombolytic drug, which is in the Phase II clinical development for treatment of patients with acute ischemic stroke. The company is also developing DP-b99, which is in the phase II clinical stage of development for the treatment of acute high-risk pancreatitis; and DP-NDD, a novel platform technology for disease-modifying drugs for the treatment of protein-misfolding neurodegenerative disorders (NDDs), such as Alzheimer’s disease and other types of dementia, Parkinson’s disease, amyotrophic lateral sclerosis, and Huntington's disease. D-Pharm LTD. was founded in 1993 and is based in Rehovot, Israel.

Founded in 1993

d-pharm ltd (DPRM) Top Compensated Officers

Co-Founder, Chief Executive Officer and Presi...
Total Annual Compensation: 768.0K
Vice President of Finance & Human Resources
Total Annual Compensation: 456.0K
Vice President of Clinical Development
Total Annual Compensation: 558.0K
Compensation as of Fiscal Year 2013.

d-pharm ltd (DPRM) Key Developments

D-Pharm Ltd. and Jiangsu Nhwa Pharmaceutical Co., Ltd. Receives Approval from the Chinese Food and Drug Administration That Allows Clinical Development of DP-VPA

D-Pharm Ltd. announced that it has been notified by its co-development partner, Jiangsu Nhwa Pharmaceutical Co., Ltd. or NHWA, that they received an approval letter from the Chinese Food and Drug Administration or C-FDA that allows clinical development of DP-VPA, through Phase 3, for epilepsy. The specific clinical protocols will be communicated to the C-FDA before the start of each new study. NHWA will begin with a bridging safety study and then proceed with a large dose-ranging Phase 2b clinical study in epilepsy patients. Prior to the IND approval, DP-VPA was granted Fast Track status, a designation designed to bring important new drugs which treat a serious or life-threatening condition and fill an unmet medical need to patients earlier. DP-VPA is a novel drug discovered and developed by D-Pharm, a derivative of the valproic acid (VPA). VPA is the active ingredient in one of the best antiepileptic drugs, with combined peak sales over $1 billion in epilepsy, migraine and bipolar disorder. In Phase 1 and 2 clinical studies DP-VPA showed superb safety and efficacy in epilepsy patients. D-Pharm and Nhwa are developing DP-VPA following a strategic agreement signed in 2011. Nhwa has responsibility for development, manufacturing, registration and marketing of DP-VPA for epilepsy in China, Hong Kong and Macau. D-Pharm has the rights for DP-VPA in the rest of the world. D-Pharm also has the right to use data produced in China to support its global development program, primarily in North American and European markets. The financial terms of the collaboration agreement include milestone payments upon achieving the development and commercial goals, as well as royalty payments from sales of DP-VPA.

D-Pharm LTD. Auditor Raises 'Going Concern' Doubt

D-Pharm LTD. filed its Annual on Feb 15, 2015 for the period ending Dec 31, 2014. In this report its auditor, Kesselman & Kesselman, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

D-Pharm LTD. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-15-2015

D-Pharm LTD. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-15-2015 . Venue: Westin St. Francis Hotel, San Francisco, California, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DPRM:IT 10.10 0.00

DPRM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for DPRM.
View Industry Companies

Industry Analysis


Industry Average

Valuation DPRM Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact D-PHARM LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at